IMV News and Press, IMV Inc. From 02/12/19

The following slide deck was published by IMV Inc. in conjunction with this Read more ...

Enrollment is underway in an 85-subject Phase 2 clinical trial, DECIDE , evaluating IMV's ( IMV ) T cell-activating immunotherapy DPX-Survivac plus chemo agent cyclophosphamide in patients with advanced platinum-sensitive and platinum-resistant ovarian cancer. More news on: IMV Inc.,...

DECIDE phase 2 clinical trial amendment successfully completed with multiple sites now open for enrollment   FDA provided guidance for future registration trial design and for a potential shorter regulatory pathway for developing DPX-Survivac as a monotherapy in certain ovarian ...

DARTMOUTH, Nova Scotia, Jan. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will participate in the BIO CEO and Investor Conference in New York City, NY. This event will take place February 11-12, 2019...